GlassScriptPhysician profile
Raafat Alameddine
NPI 1740842418
$399.72
in general payments reported to CMS, 2019-2025
13 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $225 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $94.44 | 2024-2025 | |
| Janssen Biotech, INC. | $48.66 | 2025 | Balversa, Erleada, Akeega |
| Astellas Pharma US INC | $41.92 | 2024 | Cresemba, Xtandi |
| Celgene Corporation | $39.83 | 2024-2025 | Reblozyl |
| Daiichi Sankyo INC. | $29.99 | 2024 | Injectafer |
| Mirati Therapeutics, INC. | $24.18 | 2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $22.64 | 2024 | |
| Genzyme Corporation | $19.31 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.34 | 2024 | Calquence |
| Pharmaessentia USA Corporation | $17.65 | 2025 | Besremi |
| Lilly USA, LLC | $14.96 | 2024 | Retevmo, Verzenio, Jaypirca |
| Taiho Oncology, INC. | $14.55 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.25 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raafat Alameddine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.